Your browser doesn't support javascript.
loading
Dose Fractionation of Moxifloxacin for Treatment of Tuberculosis: Impact of Dosing Interval and Elimination Half-Life on Microbial Kill and Resistance Suppression.
Drusano, G L; Rogers, Stephanie; Brown, David; Peloquin, C A; Neely, Michael; Yamada, Walter; Kim, Sarah; Almoslem, Mohammed; Schmidt, Stephan; Louie, Arnold.
Afiliação
  • Drusano GL; Institute for Therapeutic Innovation, College of Medicine, University of Florida, Orlando, Florida, USA gdrusano@ufl.edu.
  • Rogers S; Institute for Therapeutic Innovation, College of Medicine, University of Florida, Orlando, Florida, USA.
  • Brown D; Institute for Therapeutic Innovation, College of Medicine, University of Florida, Orlando, Florida, USA.
  • Peloquin CA; Infectious Diseases Pharmacodynamics Laboratory, College of Pharmacy, University of Florida, Orlando, Florida, USA.
  • Neely M; University of Southern California, Los Angeles Children's Hospital, Los Angeles, California, USA.
  • Yamada W; University of Southern California, Los Angeles Children's Hospital, Los Angeles, California, USA.
  • Kim S; Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, University of Florida, College of Pharmacy, Orlando, Florida, USA.
  • Almoslem M; Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, University of Florida, College of Pharmacy, Orlando, Florida, USA.
  • Schmidt S; Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, University of Florida, College of Pharmacy, Orlando, Florida, USA.
  • Louie A; Institute for Therapeutic Innovation, College of Medicine, University of Florida, Orlando, Florida, USA.
Antimicrob Agents Chemother ; 65(4)2021 03 18.
Article em En | MEDLINE | ID: mdl-33468465
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 / 3_ND Base de dados: MEDLINE Assunto principal: Tuberculose / Antituberculosos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Antimicrob Agents Chemother Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 / 3_ND Base de dados: MEDLINE Assunto principal: Tuberculose / Antituberculosos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Antimicrob Agents Chemother Ano de publicação: 2021 Tipo de documento: Article